MAGENTA THERAPEUTICS INC (MGTA)

Company Profile

Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.

Company Info

MAGENTA THERAPEUTICS INC

100 Technology Sq Fl 5

Cambridge MASSACHUSETTS 02139

P: 18572012700.0

CEO: Jason Gardner

Employees: 67

Website: https://www.magentatx.com/